Protuoso raises $9.5M Series A for hub-and-spoke antibody development

What's the deal? ProtuosoDealroom has a profile for this one. Try Dealroom →, a new antibody-focused biotech startup, has raised $9.5M in funding to develop a hub-and-spoke model for antibody drug development. The company joins a growing wave of biotechs adopting this decentralised approach, where a central "hub" platform supports multiple drug programmes — or "spokes" — simultaneously.

Why now? Variations on the hub-and-spoke model have blossomed across the drug development industry in recent years. The approach lets biotechs spread risk across multiple programmes while keeping a shared infrastructure at the centre, making it an attractive template for investors and founders alike.

The signal: Protuoso's $9.5M raise underscores sustained investor confidence in platform-model biotechs, even at the earliest stages. Dealroom classifies the company as "early growth," suggesting it may already have foundational assets or programmes in place beyond a pure concept — a sign that hub-and-spoke antibody developers are maturing faster as the model becomes better understood by both founders and funders.

Read more: endpoints.news